Practical Application and Particular Treatment: What the USPTO’s December 4 Memorandum Means for Life Sciences §101 Eligibility
The USPTO’s December 4, 2025 memorandum on Subject Matter Eligibility Declarations (SMEDs) seeks to raise awareness of the “underutilized path” of submitting Rule 132 declarations, referred to as “SMEDs”, for...
Jeremiah Helm Comments On How Upcoming Supreme Court ‘Skinny Label’ Case Could Impact Hatch-Waxman Litigation
In interviews with Law360 and Life Sciences Intellectual Property Review, Knobbe Martens partner Jeremiah Helm offered insights into the Supreme Court’s decision to hear a petition of the Federal Circuit’s...
Proposed Legislation to Codify “Skinny Label” Safe Harbor
On December 5, 2025, the Skinny Labels, Big Savings Act (H.R. 6485) was introduced in the House of Representatives. The bill, if enacted, would shield certain drug manufacturers who have...
MLex Quotes Jeremiah Helm on Latest Developments in Hikma’s ‘Skinny Label’ Supreme Court Bid
In a recent MLex article, Knobbe Martens partner Jeremiah Helm shared his insights on Hikma Pharmaceuticals’ bid for the Supreme Court to grant certiorari in a closely watched “skinny label”...
Life Science Considerations on the USPTO’s New Guidelines for AI-Assisted Inventorship
On November 26, 2025, the United States Patent and Trademark Office (USPTO) issued revised guidelines for determining inventorship of AI-assisted inventions,[1] which is a significant development in life science innovations,...
USPTO’s Automated Search Pilot: Through a Biotech Lens
In October 2025, the U.S. Patent and Trademark Office (USPTO) launched the “Artificial Intelligence Search Automated Pilot Program,” or ASAP!, an initiative to identify potential prior art using artificial intelligence...
Patent Exclusivity and Price Controls: Teva v. Kennedy
On November 20, 2025, the D.C. District Court issued its opinion [1] in a lawsuit where Teva Pharmaceuticals USA, Inc. challenged the validity of the Medicare Drug Price Negotiation Program...
Knobbe Martens Receives Top-Tier Recognitions in Patexia ANDA Litigation Intelligence Report
IRVINE, Calif., December 1, 2025 – Knobbe Martens is pleased to share that the firm was recognized among the best performing and most active Hatch-Waxman litigation firms in Patexia’s 2025...
Purdue Pharma’s $7.4 Billion Chapter 11 Plan Formally Approved
A federal bankruptcy court on November 18 formally approved Purdue’s $7.4 billion Chapter 11 plan to settle thousands of opioid-related lawsuits. The plan requires (1) a $6.5 billion contribution from...
Jeremiah Helm and Sean Murray’s Discuss Extension of Printed Matter Doctrine in Law360 Column
In their latest Law360 column discussing noteworthy Federal Circuit cases, partners Jeremiah Helm and Sean Murray examine the recent decision in Bayer Pharma Aktiengesellschaft v. Mylan Pharmaceuticals Inc., and how...
Knobbe Martens Advises Pacira BioSciences in Exclusive License Agreement with AmacaThera for Novel Long-Acting Analgesic
Agreement will support the development and commercialization of non-opioid therapy for postsurgical pain control IRVINE, Calif., November 4, 2025 – A team from Knobbe Martens advised Pacira BioSciences, Inc. in...
Knobbe Martens Names New Chairs of Market-Leading Trademark and Brand Protection Group
IRVINE, Calif., October 22, 2025 – Knobbe Martens, one of the nation’s largest intellectual property law firms, is pleased to announce that Charlene Azema and Gregory Phillips have been named...
San Diego Business Journal Names Robert Hilton and Daniel Hughes Among “Leaders of Influence in Law”
SAN DIEGO, October 21, 2025 – Knobbe Martens is pleased to share that partners Robert Hilton and Daniel Hughes have been recognized as “Leaders of Influence in Law” by the...
Carol Pitzel Cruz and Andrea Cheek Named Among “Women Worth Watching in Leadership” by Profiles in Leadership Journal
SEATTLE and WASHINGTON, D.C., October 3, 2025 – Knobbe Martens congratulates partners Carol Pitzel Cruz and Andrea Cheek for their recognition as “Women Worth Watching in Leadership” by Profiles in...
Knobbe Martens’ Standout Life Sciences Work Recognized in Annual LMG Rankings
Firm receives top-tier rankings for patent strategy, prosecution and litigation across life sciences industry IRVINE, Calif., October 1, 2025 – Knobbe Martens is proud to share that Legal Media Group...
Carol Pitzel Cruz Named ‘Winning Litigator’ Finalist by The National Law Journal
Pitzel Cruz’s selection follows recent recognition as ‘Hatch-Waxman Litigator of the Year’ at LMG Life Sciences Awards SEATTLE, September 9, 2025 – Knobbe Martens is pleased to share that partner...
Lawdragon Names 17 Knobbe Martens Partners Among ‘Leading Litigators in America’
IRVINE, Calif., September 8, 2025 – Knobbe Martens is pleased to share that 17 of the firm’s partners have been recognized in the 2026 edition of the Lawdragon 500 Leading...
Knobbe Martens’ Hatch-Waxman Practice Takes Home Multiple Honors at 2025 LMG Life Sciences Americas Awards
Firm named ‘Hatch-Waxman Litigation Firm of the Year’; Carol Pitzel Cruz receives ‘Hatch-Waxman Litigator of the Year’ award IRVINE, Calif., September 5, 2025 – Knobbe Martens is pleased to share...
Dozens of Knobbe Martens Lawyers Featured in “Best Lawyers” 2026 Guide
IRVINE, Calif., August 21, 2025 – Knobbe Martens is pleased to share that dozens of the firm’s lawyers, representing a range of practice areas and offices across the country, have...
Knobbe Martens Advises Ligand Pharmaceuticals on $460 Million Convertible Notes Offering
SAN DIEGO, August 19, 2025 – Knobbe Martens partners Joe Reisman and Ryan Melnick serve as IP counsel to Ligand Pharmaceuticals Incorporated, a biopharmaceutical royalty aggregator. Dr. Reisman and Dr....
Knobbe Martens Partners Recognized as Top IP Strategists in 2025 IAM Strategy 300 Guide
IRVINE, Calif., August 14, 2025 – Knobbe Martens is pleased to share that a number of the firm’s partners have been recognized in the 2025 edition of the IAM Strategy...
